Skip to content

9 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial

Treatment with mitiperstat, intended to target the neutrophil–MPO inflammatory pathway, did not improve symptoms or exercise function in individuals with heart failure with preserved or mildly reduced ejection fraction.

Lars H. Lund, Carolyn S. P. Lam, P. E. Pizzato et al. · 1 citation
Aug 2026

Venous thromboembolism in 5-year cancer survivors: a nationwide cohort study.

Survivors of all 21 cancer subtypes had a higher associated rate of VTE compared with the background population, with the highest incidence rates found for multiple myeloma.

A. Yafasova, Guo-Li Sun, M. Hutchings et al. · 0 citations
Open access Oct 2026

Left Atrial Enlargement Identifies Risk of Stroke Independent of Atrial Fibrillation.

BACKGROUND Left atrial (LA) enlargement has been proposed to increase stroke risk independent of atrial fibrillation (AF), but evidence accounting for AF over time is limited. We tested whether the association between LA enlargement and stroke persist independent of new-onset AF. METHODS In this observational study,...

J. J. Loft, J. Kühl, M. Pham et al. · 0 citations
Oct 2026

Inflammation, Infarct Size and 10-Year Mortality in STEMI Patients Stratified by the ORBI Risk Score: A DANAMI-3 Sub-study.

BACKGROUND The ORBI Risk Score predicts in-hospital cardiogenic shock after primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). Whether high-risk patients also have more systemic inflammation, larger infarcts and higher long-term mortality is not known. METHODS In a DANAMI...

J. Kunkel, J. Lønborg, M. Frydland et al. · 0 citations
Aug 2026

Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial.

BACKGROUND SGLT2 inhibitors (SGLT2i) reduce mortality in left heart failure. In pulmonary arterial hypertension (PAH), preclinical data suggest SGLT2i improve right ventricular function through metabolic modulation and inhibition of vascular remodeling via smooth muscle cell pathways. The DAPAH trial evaluated whether...

M. Ersbøll, J. Kjærgaard, K. Waidtløw et al. · 1 citation
Open access Aug 2026

Prognostic Impact of Kidney Function before Transcatheter Aortic Valve Implantation - A Nationwide study

Prognosis after transcatheter aortic valve implantation (TAVI) keeps improving, yet some high-risk groups persist with chronic kidney disease being one. Contemporary data on the prognostic importance of pre-TAVI kidney function are sparse, leaving uncertainty regarding which patients derive limited benefit from T...

Martha Meibom, J. Petersen, Victoria Mikkelsen et al. · 0 citations
Sep 2026

Complete revascularization according to age in patients with ST-segment elevation myocardial infarction and multivessel disease: 10-year outcome from the DANAMI-3-PRIMULTI trial.

In patients aged ≥75 years, clear evidence of a long-term (10 years) benefit of complete revascularization was not demonstrated, and the finding should be interpreted as inconclusive.

Yan Zhou, B. T. Özbek, J. Marquard et al. · 0 citations
Open access Sep 2026

Artificial intelligence detection of heart failure on coronary computed tomography angiography: external validation in patients with non-ST-segment elevation acute coronary syndrome

Artificial intelligence-based CCTA analysis identified a large low-risk subgroup and a smaller subgroup at increased HF risk, supporting further evaluation of opportunistic HF assessment from CCTA.

A. O. Olesen, K. Miger, S. Ørting et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.